| Bispecific GRPR-antagonistic anti-PSMA/GRPR heterodimer for PET and SPECT diagnostic imaging of prostate cancer B Mitran, Z Varasteh, A Abouzayed, SS Rinne, E Puuvuori, M De Rosa, ... Cancers 11 (9), 1371, 2019 | 39 | 2019 |
| Trastuzumab cotreatment improves survival of mice with PC‐3 prostate cancer xenografts treated with the GRPR antagonist 177Lu‐DOTAGA‐PEG2‐RM26 B Mitran, SS Rinne, MW Konijnenberg, T Maina, BA Nock, M Altai, ... International journal of cancer 145 (12), 3347-3358, 2019 | 36 | 2019 |
| Comparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2 A Vorobyeva, A Sсhulga, E Konovalova, R Güler, B Mitran, J Garousi, ... International journal of oncology 54 (4), 1209-1220, 2019 | 30 | 2019 |
| Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model B Mitran, R Güler, FP Roche, E Lindström, RK Selvaraju, F Fleetwood, ... Theranostics 8 (16), 4462, 2018 | 29 | 2018 |
| Heterodimeric radiotracer targeting PSMA and GRPR for imaging of prostate cancer—optimization of the affinity towards PSMA by linker modification in murine model F Lundmark, A Abouzayed, B Mitran, SS Rinne, Z Varasteh, M Larhed, ... Pharmaceutics 12 (7), 614, 2020 | 28 | 2020 |
| Indirect radioiodination of DARPin G3 using N-succinimidyl-para-iodobenzoate improves the contrast of HER2 molecular imaging A Vorobyeva, A Schulga, SS Rinne, T Günther, A Orlova, S Deyev, ... International journal of molecular sciences 20 (12), 3047, 2019 | 28 | 2019 |
| Pet and spect imaging of the egfr family (Rtk class i) in oncology SS Rinne, A Orlova, V Tolmachev International Journal of Molecular Sciences 22 (7), 3663, 2021 | 27 | 2021 |
| On the prevention of kidney uptake of radiolabeled DARPins M Altai, J Garousi, SS Rinne, A Schulga, S Deyev, A Vorobyeva EJNMMI research 10 (1), 1-8, 2020 | 25 | 2020 |
| Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111 SS Rinne, CD Leitao, B Mitran, TZ Bass, KG Andersson, V Tolmachev, ... Scientific reports 9 (1), 1-11, 2019 | 25 | 2019 |
| Feasibility of imaging EpCAM expression in ovarian cancer using radiolabeled DARPin Ec1 A Vorobyeva, E Konovalova, T Xu, A Schulga, M Altai, J Garousi, ... International journal of molecular sciences 21 (9), 3310, 2020 | 24 | 2020 |
| Influence of molecular design on the targeting properties of ABD-fused mono-and bi-valent anti-HER3 affibody therapeutic constructs M Altai, CD Leitao, SS Rinne, A Vorobyeva, C Atterby, S Ståhl, ... Cells 7 (10), 164, 2018 | 24 | 2018 |
| Synthesis and preclinical evaluation of radio-iodinated GRPR/PSMA bispecific heterodimers for the theranostics application in prostate cancer A Abouzayed, CB Yim, B Mitran, SS Rinne, V Tolmachev, M Larhed, ... Pharmaceutics 11 (7), 358, 2019 | 23 | 2019 |
| Molecular design of HER3-targeting affibody molecules: Influence of chelator and presence of HEHEHE-tag on biodistribution of 68Ga-labeled tracers C Dahlsson Leitao, SS Rinne, B Mitran, A Vorobyeva, KG Andersson, ... International journal of molecular sciences 20 (5), 1080, 2019 | 23 | 2019 |
| Incorporation of a hydrophilic spacer reduces hepatic uptake of HER2-targeting affibody–DM1 drug conjugates H Ding, M Altai, SS Rinne, A Vorobyeva, V Tolmachev, T Gräslund, ... Cancers 11 (8), 1168, 2019 | 22 | 2019 |
| Evaluation of the therapeutic potential of a HER3-binding affibody construct TAM-HER3 in comparison with a monoclonal antibody, seribantumab A Orlova, TZ Bass, SS Rinne, CD Leitao, M Rosestedt, C Atterby, ... Molecular pharmaceutics 15 (8), 3394-3403, 2018 | 22 | 2018 |
| Preclinical Evaluation of 99mTc-ZHER2: 41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake M Oroujeni, SS Rinne, A Vorobyeva, A Loftenius, J Feldwisch, ... International journal of molecular sciences 22 (5), 2770, 2021 | 21 | 2021 |
| Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26 B Mitran, H Thisgaard, S Rinne, JH Dam, F Azami, V Tolmachev, A Orlova, ... Scientific reports 9 (1), 1-11, 2019 | 19 | 2019 |
| 66 Ga-PET-imaging of GRPR-expression in prostate cancer: production and characterization of [66 Ga] Ga-NOTA-PEG 2-RM26 SS Rinne, A Abouzayed, K Gagnon, V Tolmachev, A Orlova Scientific reports 11 (1), 1-12, 2021 | 17 | 2021 |
| Increase in negative charge of 68 Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules SS Rinne, CD Leitao, J Gentry, B Mitran, A Abouzayed, V Tolmachev, ... Scientific reports 9 (1), 1-10, 2019 | 16 | 2019 |
| Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy A Vorobyeva, K Westerlund, B Mitran, M Altai, S Rinne, J Sörensen, ... Scientific reports 8 (1), 1-10, 2018 | 15 | 2018 |
